"ada standards of care (2025): pharmacologic approaches to glycaemic treatment" MCQ (SBA): ASCVD

Instant feedback + full explanation. One question, done properly.

Moderateadding a GLP‑1 RA with proven CV benefit reduces eventsASCVD"ada standards of care (2025): pharmacologic approaches to glycaemic treatment"

A 61-year-old with diabetes and ASCVD has A1c 7.8% on metformin and SGLT2 inhibitor. To further reduce CV events per ADA 2025

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.

"ada standards of care (2025): pharmacologic approaches to glycaemic t